January 13, 2020 - Page 22 of 22

NASDAQ Companies - January 13, 2020

Chi-Med Initiates a Phase II Trial of Surufatinib in Combination with Tuoyi in Patients with Advanced Solid Tumors

LONDON, Jan. 13, 2020 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase II study […]

NASDAQ Companies - January 13, 2020

Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications

– Partial Responses seen in liver, melanoma, gastro-esophageal junction, and head and neck cancers –– Encouraging demonstration of the potential […]

NYSE Companies - January 13, 2020

Caledonia Mining Corporation Plc: Issue of Securities and Long Term Incentive Awards

ST HELIER, Jersey, Jan. 13, 2020 (GLOBE NEWSWIRE) — Caledonia Mining Corporation Plc (the “Company” or “Caledonia”) (NYSE American: CMCL; AIM: […]

NYSE Companies - January 13, 2020

Caledonia Mining Corporation Plc: Record quarterly gold production at Blanket Mine

ST HELIER, Jersey, Jan. 13, 2020 (GLOBE NEWSWIRE) — Caledonia Mining Corporation Plc (TSX: CAL) (NYSE American: CMCL) (LSE: CMCL) (“Caledonia” […]

NASDAQ Companies - January 13, 2020

Euronet Worldwide to Publish Missing Children Alerts on Its ATM Screens Through Agreement with AMBER Alert Europe

LEAWOOD, Kan., Jan. 13, 2020 (GLOBE NEWSWIRE) — Euronet Worldwide (NASDAQ: EEFT), a leading global financial technology solutions and payments […]

NASDAQ Companies - January 13, 2020

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Preliminary data from the Phase 1 CYCLE-1 trial are expected during second half 2020MONT-SAINT-GUIBERT, Belgium, Jan. 13, 2020 (GLOBE NEWSWIRE) […]

NASDAQ Companies - January 13, 2020

ObsEva and Yuyuan BioScience Technology Announce Sublicense Agreement to Develop and Commercialize Nolasiban in the People’s Republic of China

Geneva, Switzerland, 13 January 2020 – ObsEva and Yuyuan BioScience Technology (“Yuyuan”) today announced that they have entered into a […]

NASDAQ Companies - January 13, 2020

Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy

Primary endpoint met at all doses: ensifentrine produced clinically and statistically significant dose-dependent improvements in lung functionClinically relevant secondary endpoints […]